Alerts
Holiday Hours Information

In recognition of the Christmas and New Year’s holidays, some of The University of Kansas Cancer Center’s offices will have modified hours on Wednesday, December 25, and Wednesday, January 1.

Skip Navigation

A Phase 2 Study of Dabrafenib NSC 763760 with Trametinib NSC 763093 after Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma HGG

Brief Summary

Type:
Brain Tumors / Neurologic Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03919071

Study #:
cmh - ACNS1723

Start Date:
Sep 03, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03919071

View Complete Trial Details & Eligibility at ClinicalTrials.gov